中山偶尔屁股大便出血正常吗(中山大便出血血颜色鲜红色) (今日更新中)

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

LOS ANGELES, May 6 (Xinhua) -- Limiting prolonged bottle use in children may be an effective way to help prevent obesity, a new study suggests.For the study, researchers from the Center for Obesity Research and Education at Temple University (CORETU) and the Ohio State University College of Public Health analyzed data from 6,750 children to estimate the association between bottle use at 24 months of age and the risk of obesity at 5.5 years of age, according to the Science Daily on Friday.Of the children studied, 22 percent were prolonged bottle users, meaning that at two years of age they used a bottle as their primary drink container and/or were put to bed with a calorie- containing bottle.The findings showed that nearly 23 percent of the prolonged bottle users were obese by the time they were 5.5 years old."Children who were still using a bottle at 24 months were approximately 30 percent more likely to be obese at 5.5 years, even after accounting for other factors such as the mother's weight, the child's birth weight, and feeding practices during infancy," said Dr. Robert Whitaker at CORETU, lead author of the study.Drinking from a bottle beyond infancy may contribute to obesity by encouraging the child to consume too many calories, the researchers noted."A 24-month-old girl of average weight and height who is put to bed with an eight-ounce bottle of whole milk would receive approximately 12 percent of her daily caloric needs from that bottle," explained co-author Rachel Gooze.Gooze noted that weaning children from the bottle by the time they are one year of age is unlikely to cause harm and may prevent obesity. The authors suggested that pediatricians and other health professionals work with parents to find acceptable solutions for stopping bottle use at the child's first birthday.The findings adds new evidence to the theory that obesity prevention should begin before children enter school, the researchers said.

BEIJING, Jan. 25 (Xinhua) -- China's 11 government departments have jointly released a guideline outlining major measures to lessen noise pollution amid rising noise disputes and complaints, the Ministry of Environmental Protection said Tuesday.The ministry's spokesperson, Tao Detian, said Tuesday the country saw rising complaints about noise pollution, which has caused an increasingly negative impact on the living environment in recent years.The 26-article guideline focuses on addressing noise pollution in fields including industry, construction, traffic and people's daily lives.Further, the regulation bans businesses from using acoustic instruments outdoors to lure customers.Also, heavy noise polluters are banned from entering industrial parks, according to the guideline.Moreover, motor vehicles should strictly observe speed limits, traffic restrictions and use of auto horns around "noise-sensitive buildings" such as hospitals, schools, government organs, scientific research institutions and residential buildings, it said.According to the guideline, government departments would also impose higher fines on noise polluters and collect fees for "discharges of excessive noise," in accordance with law.The newly issued document calls on various government agencies, such as the ministries on environmental protection, science and technology, public security, finance, housing, transportation and railways, to make coordinated efforts to curb pollution.Further, government organs could launch regular inspection campaigns in major cities, it said.According to the guideline, government agencies will set up a system to examine sound-proof qualities of civilian buildings and provide a list of major noise pollution sources by the end of this year.Also, the guideline ordered major cities to establish an automatic noise monitoring system and to equip each city in the country with at least one noise display screen by the end of 2011.

BEIJING, May 21 (Xinhua) -- China's State Food and Drug Administration (SFDA) issued a circular on Friday banning the use of Nimesulide, an anti-inflammatory drug, for children under the age of 12, considering potential side-effects such as liver and kidney damage.Nimesulide is a non-steroidal anti-inflammatory drug that first became available in Italy in 1985. It is now used in more than 50 countries and regions.The drug entered Chinese markets in 1997.According to the SFDA, while common adverse reactions to the drug include vomiting and stomache, domestic and overseas statistics indicate that more severe issues are related to the drug, such as blood coagulation disorders, decreased white blood cells and damage to liver and kidney.Previously, the SFDA only prevented the use of the drug among children one year old or younger.Also on Friday, the SFDA ordered the suspension of the production, sales and use of Duxil (almitrine and raubasine compound) due to its "unobvious" efficacy.According to the SFDA, clinical research found "little" evidence proving the drug effectively improves the cognitive ability for patients suffering vascular cognitive impairment.The drug was supposed to treat symptoms related to cognition and sensory nerve damage.The moves came after a two-month nationwide campaign was launched earlier this month to probe the quality of essential drugs and ensure drug safety.Official figures show that China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions in 2010, up 8.4 percent compared with those in 2009.Among the total, 109,991 cases involved new or severe adverse reactions, a year-on-year increase of 16.2 percent.

WASHINGTON, April 29 (Xinhua) -- A U.S. appeals court ruled on Friday that the Obama administration can continue the taxpayer- funding for human embryonic stem cell research.The U.S. Court of Appeals in Washington overturned a preliminary federal court order that would have blocked the U.S. Health and Human Services Department and the National Institutes of Health (NIH) from spending government money on embryonic stem cells research."Today's ruling is a victory for our scientists and patients around the world who stand to benefit from the groundbreaking medical research they're pursuing," said Nicholas Papas, a White House spokesman.U.S. President Barack Obama has been trying to expand government funding for human embryonic stem cells research, saying that years of progress on finding cures for spinal cord injuries, Parkinson's disease and other diseases would be lost without the government support on this field.Opponents have been arguing the research is unacceptable because embryonic stem cells can only be obtained through destroying human embryos.Last August, a federal judge ruled that the government-backed embryonic stem cell research violated the law because embryos were destroyed in the process and it jeopardized the position of researchers using adult stem cells for winning federal grants.The government immediately appealed to the ruling, and the appeals court said the research could continue at the NIH before the judge ruled on the case.

来源：资阳报